DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, announced today the publication of a study in Nature Scientific Reports that demonstrates that DiaCarta’s cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients. DocWire News spoke with Mike Powell, PhD, […]

With so much focus on the Delta variant and breakthrough COVID, there is an escalating public health threat that requires our attention and action: Long COVID. It is on track to long outlast the pandemic, and its enduring impact on public health in America could be more profoundly devastating than we can currently predict. Formally […]

What if a smartphone could detect your patients’ risk of developing a chronic condition such as type 2 diabetes, heart disease or stroke? What if patients could use a smartphone app to initiate a scan that provided direct feedback on a suspicious lesion on their skin? Through an easy-to-use app, suppose your patients could measure […]